XML 20 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Equity (Unaudited) - USD ($)
shares in Millions, $ in Millions
Total
Common stock
Treasury stock
Additional paid-in capital
Retained earnings
Accumulated other comprehensive loss
Noncontrolling interest
Beginning balance at Dec. 31, 2019 $ (8,172) $ 18 $ (24,504) $ 15,193 $ 4,717 $ (3,596) $ 0
Beginning balance (in shares) at Dec. 31, 2019   1,479          
Increase (Decrease) in Stockholders' Equity              
Net earnings (loss) attributable to AbbVie Inc. 2,272 $ 0 0 0 2,272 0 0
Other comprehensive income (loss), net of tax 161 0 0 0 0 161 0
Dividends declared (3,859) 0 0 0 (3,859) 0 0
Common shares and equity awards issued for acquisition of Allergan plc 24,409 $ 0 23,166 1,243 0 0 0
Common shares issued to Allergan plc stockholders (in shares)   286          
Purchases of treasury stock (662) $ 0 (662) 0 0 0 0
Purchases of treasury stock (in shares)   (7)          
Stock-based compensation plans and other 559 $ 0 42 517 0 0 0
Stock-based compensation plans and other (in shares)   6          
Change in noncontrolling interest 24 $ 0 0 0 0 0 24
Ending balance at Jun. 30, 2020 14,732 $ 18 (1,958) 16,953 3,130 (3,435) 24
Ending balance (in shares) at Jun. 30, 2020   1,764          
Beginning balance at Mar. 31, 2020 (7,415) $ 18 (25,110) 15,401 5,973 (3,697) 0
Beginning balance (in shares) at Mar. 31, 2020   1,477          
Increase (Decrease) in Stockholders' Equity              
Net earnings (loss) attributable to AbbVie Inc. (738) $ 0 0 0 (738) 0 0
Other comprehensive income (loss), net of tax 262 0 0 0 0 262 0
Dividends declared (2,105) 0 0 0 (2,105) 0 0
Common shares and equity awards issued for acquisition of Allergan plc 24,409 $ 0 23,166 1,243 0 0 0
Common shares issued to Allergan plc stockholders (in shares)   286          
Purchases of treasury stock (19) $ 0 (19) 0 0 0 0
Purchases of treasury stock (in shares)   0          
Stock-based compensation plans and other 314 $ 0 5 309 0 0 0
Stock-based compensation plans and other (in shares)   1          
Change in noncontrolling interest 24 $ 0 0 0 0 0 24
Ending balance at Jun. 30, 2020 14,732 $ 18 (1,958) 16,953 3,130 (3,435) 24
Ending balance (in shares) at Jun. 30, 2020   1,764          
Beginning balance at Dec. 31, 2020 13,097 $ 18 (2,264) 17,384 1,055 (3,117) 21
Beginning balance (in shares) at Dec. 31, 2020   1,765          
Increase (Decrease) in Stockholders' Equity              
Net earnings (loss) attributable to AbbVie Inc. 4,319 $ 0 0 0 4,319 0 0
Other comprehensive income (loss), net of tax 14 0 0 0 0 14 0
Dividends declared (4,634) 0 0 0 (4,634) 0 0
Purchases of treasury stock (797) $ 0 (797) 0 0 0 0
Purchases of treasury stock (in shares)   (7)          
Stock-based compensation plans and other 591 $ 0 39 552 0 0 0
Stock-based compensation plans and other (in shares)   9          
Change in noncontrolling interest 4 $ 0 0 0 0 0 4
Ending balance at Jun. 30, 2021 12,594 $ 18 (3,022) 17,936 740 (3,103) 25
Ending balance (in shares) at Jun. 30, 2021   1,767          
Beginning balance at Mar. 31, 2021 13,733 $ 18 (3,017) 17,712 2,292 (3,295) 23
Beginning balance (in shares) at Mar. 31, 2021   1,766          
Increase (Decrease) in Stockholders' Equity              
Net earnings (loss) attributable to AbbVie Inc. 766 $ 0 0 0 766 0 0
Other comprehensive income (loss), net of tax 192 0 0 0 0 192 0
Dividends declared (2,318) 0 0 0 (2,318) 0 0
Purchases of treasury stock (10) $ 0 (10) 0 0 0 0
Purchases of treasury stock (in shares)   0          
Stock-based compensation plans and other 229 $ 0 5 224 0 0 0
Stock-based compensation plans and other (in shares)   1          
Change in noncontrolling interest 2 $ 0 0 0 0 0 2
Ending balance at Jun. 30, 2021 $ 12,594 $ 18 $ (3,022) $ 17,936 $ 740 $ (3,103) $ 25
Ending balance (in shares) at Jun. 30, 2021   1,767